Information mensuelle sur le nombre total d’actions et de droits de vote composant le capital social

Exosens reported +23.5% revenue growth in Q3 2026, driven by stronger demand and faster-than-expected capacity expansion. The company remains on track to meet its upgraded 2026 outlook and is supporting the deployment of next-generation nuclear technologies in the U.S. under the Department of Energy's Reactor Pilot Program.